Trials / Not Yet Recruiting
Not Yet RecruitingNCT06245018
A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor
An Open, Dose Escalation and Extension Platform Trial to Evaluate the Safety, Pharmacological and Preliminary Efficacy of Human Induced Pluripotent Stem Cell Derived Natural Killer Cells (iNK) in Chinese Subjects With Solid Tumor
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Nuwacell Biotechnologies Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.
Detailed description
Solid tumor is a disease with high mortality rates. The aim of this trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | iNK Injection | Subjects will receive about 4 cycles of iNK |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2027-03-01
- Completion
- 2030-03-01
- First posted
- 2024-02-07
- Last updated
- 2024-02-07
Source: ClinicalTrials.gov record NCT06245018. Inclusion in this directory is not an endorsement.